COVID-19

Vaccine stocks sprout on the stock market

November 29, 2021

13:38

The time has come for a rally in the stock markets on Monday after the arrival of the Omicron variant that capsized the indices on Friday.

If energy stocks, seriously shaken on Friday, primarily fueled the rally observed on Monday, several stocks known as the “crown” sparked.

Read also

At the forefront we find the actions of the laboratories launched in the vaccine race. Modern

, one of the first groups, with Pfizer and BioNTech, to bring out its anti-covid vaccine, rose more than 20% in the shortened session on Friday. The stock continues to gain nearly 10% Monday in “pre-market” trading, resuming its spot as the S&P 500’s best performer since the beginning of the year.

“We advise overweighting Moderna shares because SARS-CoV-2 will not go away and will provide years of future income.”

Piper Sandler Analysts

Moderna mobilized hundreds of workers on Thanksgiving Day to begin work on the Omicron bypass. According to the medical director of American biotechnology, the mRNA technology will be able to adapt to the new variant. A solution should be found in early 2022.

A projection that has analysts at investment bank Piper Sandler affirm that “Moderna is in a better position to develop the new Covid-19 vaccine and that it now has the capacity to manufacture several hundred million doses per month.” In a note to clients, Piper Sandler says to “overweight” Moderna shares now because “SARS-CoV-2 will not go away and will provide years of future income.”

Read also

+17.5 billion

of dollars

Pfizer’s market capitalization now exceeds $ 303 billion. It grew by $ 17.5 billion in the Friday session alone, a session interrupted due to Thanksgiving.

Pfizer au record

Same observation from Pfizer side

, even if the variation is less dizzying than that shown by Moderna. But Pfizer is much larger. The pharmaceutical group took more than 6% on Friday, adding a whopping $ 17.5 billion to its stock market valuation to sign a new all-time high. Pfizer is still on track Monday thanks to its vaccine developed in collaboration with BioNTech, which is on track to become the best-selling pharmaceutical product annually.

Closer to home, in Paris, Eurofins action

started this Monday session with a bang. The French laboratory was wanted after the launch of new PCR tests to detect the Omicron variant.

Glove maker rubs hands

More anecdotal, the world’s largest glove manufacturer, Malaysian group Top Glove, jumped 30% in session on Monday, reaching the limit allowed in the Malaysian market.

Before the day’s hike, Top Glove’s share had fallen more than half this year. They were one of the most sought-after values ​​in 2020 at the beginning of the pandemic. Between March 2020 and July of the same year, the company saw its price rise by more than 350%.

WeaPlay, WordPress Theme, Business Consulting Nulled, Avada 7.4 Nulled, Newspaper – News & WooCommerce WordPress Theme, Nulledfire, Elementor Pro Weadown, Astra Pro Nulled, Plugins, Rank Math Seo Pro Weadown, Woodmart Theme Nulled, Elementor Pro Weadown,Woodmart Theme Nulled, Wordfence Premium Nulled, Flatsome Nulled, Yoast Nulled, Woocommerce Custom Product Ad, Jannah Nulled, Dokan Pro Nulled, Fs Poster Plugin Nulled, Jnews 8.1.0 Nulled, PW WooCommerce Gift Cards Pro Nulled, Newspaper 11.2, Premium Addons for Elementor, Slider Revolution Nulled, Wpml Nulled, PHP Script, WP Reset Pro, Consulting 6.1.4 Nulled

Back to top button